已阅读5页,还剩20页未读, 继续免费阅读
版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
Todd A Fehniger Hematology Grand Round March 13, 2009,Lenalidomide therapy for untreated acute myeloid leukemia in older adults ( 60 years of age),Disclosure,Clinical study funded in part by Celgene Non-FDA approved use of Revlimid (lenalidomide),Case,71 yo M presented with dyspnea, fatigue, and pancytopenia Performance status: ECOG 1 PMH: HTN, GERD, BPH PE: petechiae, pale CBC WBC 1900/uL (ANC 190/uL) Hgb 6.7 g/dL Plts 74,000/uLf Differential: 33% blasts,Blood 113: 1002, 2009,Case,Bone marrow biopsy and aspirate 30% cellular 90% myeloblasts FAB M0 (undifferentiated) Flow: CD34+CD33+CD13+CD117+ Routine cytogenetics: trisomy 13 47,XY+135/46,XY15 FLT3ITD: Positive,Blood 113: 1002, 2009,Case: Dx Bone Marrow and Cytogenetics,BM Aspirate,Leder stain,Acute Myeloid Leukemia in patients 60 year old,Median age of AML is 65-70 13, 410 new AML cases / 8,990 deaths in 2007 14.5/100,000 in adults 60 years 0.7/100,00 in adults 60 years Majority of patients do not receive specific therapy (best supportive care) Median survival 1 year,Older AML: Prognosis and Standard Therapies?,7+3: median survival 8-13 months Low dose ara-c: 9 months NCCN: Investigational agents recommended as 1st line therapy Prognosis, Results with current therapy options, and overview of investigational agents Summarized in Mike Martins WashU Heme/Onc grand rounds presentation from February 2008 Martin and Abboud. Bood Rev 22:311, 2008 Eliah Estey J Clin Oncol 25:1908, 2007,Older AML biology: continuum with myelodysplastic syndrome (MDS),Cytogenetics in older AML lower percentage of favorable risk cytogenetics t(8;14), t(15;17), inv(16) Higher percentage of unfavorable cytogenetics -5, -7, +8, complex Frequently arises from MDS or initial diagnoses as AML with multilineage dysplasia Resistant to traditional chemotherapy (MDR1) Presentation with a hypoproliferative, MDS type picture common,MDS and lenalidomide,Efficacy of lenalidomide in MDS. List A et al. NEJM 352:549 2005 Lenalidomide in MDS with 5q deletion. List A et al. NEJM 355:1456,2006 Phase 2 study of lenalidomide in transfusion-dependent, low and int-1 risk MDS with karyotypes other than deletion 5q. Blood 111:86, 2008. A small number of patients with clonal cytogenetic abnormalities (non-5q-) and excess blasts had cytogenetic responses and CRs,(I presented this topic at WashU Heme/Onc Grand Rounds 6/10/2005 as a fellow: my interest led to the current study!),Hypothesis: Lenalidomide has activity in acute myeloid leukemia,One of my fellow clinical protocols (with Ravi Vij),Study design,Phase II, single-institution, investigator-initiated, prospective, open-label study Simon 2 stage design (n=12 evaluable in stage 1) Primary Endpoint: CR (CRc/CRm/CRi) IWG criteria with addition of SD Secondary Endpoints: safety, IWG response criteria, overall survival, event-free survival, and duration of remission Eligibility: Untreated AML age 60 yo (prior MDS, therapy related, de novo all eligible) Exclude: 5q- and favorable risk cytogenetics,Stage 1 / Cohort 1 Schema,Cheson JCO 2007,IWG Criteria for AML,06-0907: Stage 1 (Cohort 1) Results,WHO IWG Criteria: (n=15 total patients) CRc: 1 (duration: 9 months) PR: 2 (duration: 6 and 12 months - ongoing) SD: 4 (duration: 3, 3, 4, 7 months) Treatment failure indeterminate cause: 6 Rash, Sepsis, Cardiac Arrest Progressive disease 2 cycles Len (n=3) Morphologic leukemia free BM at d15 w/ PD at d30 Treatment failure resistant disease: 2,Len,(No Len),Stage 2 / Cohort 2 Schema,Stage 2 = Cohort 2 N=27 patients Independent analysis,Preliminary Results Cohort 2 (n=25 so far),Unpublished,Case: Clinical Course Pt. 007,Case: Follow-up,BM (%),0,20,40,60,80,100,Day 0,Day 15,Day 30,Day 75,LD,cycle 1,BM blasts,BM cellularity,WBC count,Hemoglobin (g/dL),0,2,4,6,8,10,12,Day 0,Day 15,Day 30,Day 75,LD,cycle 1,Hemoglobin,Platelets,0,2.0,4.0,6.0,8.0,10.0,0,50,100,200,250,300,Platelets (x103/L),WBC (x 103/L),150,CR Aspirate 100X,CR Leder 10X,CR Leder 100X,Lenalidomide: Mechanism?,Block Angiogenesis,Direct Effects on tumor,Alter cytokine profiles,Immune modulation,Phosphatase modulation,Lenalidomide (Revlimid),Multiple Myeloma,Lymphoma,MDS (w/ 5q-),Activity,Potential Mechanism(s),CLL,AML,Lenalidomide has activity in AML how does it work?,Modulation of NK cell responses? Correlative studies evaluating NK cells prior to, during, and after therapy Direct effects on AML? BM blasts at Dx: In vitro lenalidomide exposure, follow blast cell death compared to vehicle; correlation to response? Leukemia microenvironment? Flow for CXCR4 on AML blasts,This would be a great project for a fellow!,Acknowledgments,Ravi Vij Alissa Nelson Kim T
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 江苏省连云港市海头高级中学高三下学期第五次调研考试新高考数学试题及答案解析
- 人工智能语音助手服务协议
- 四川省南充市重点中学新高考数学押题试卷及答案解析
- 浙江省杭州市下学期高三2月开学模拟(网络考试)新高考数学试题
- 人工智能辅助法律咨询协议
- 文言文阅读训练:《清史稿-靳辅传》(附答案解析与译文)
- 个人欠款的协议书
- 5G通信服务协议
- 酒店行业portal认证解决方案
- 工作调动协议书
- 企业安全防汛知识培训
- 【中药学】化痰止咳平喘药
- 医院消防安全培训ppt完整版
- 《树立自信心》课件
- 供电局消防培训课件
- 电厂防暑降温知识讲座
- 国开2023秋《政-府-经-济-学》形考任务二参考答案
- 精细化抹灰操作方案
- 品牌标识系统化方案
- 全军性财务管理制度
- 2022年江苏苏州中考数学试题【含答案】
评论
0/150
提交评论